Dr. Rizwan Romee is an associate professor of medicine at Harvard Medical School and an oncologist at Dana Farber Cancer Institute (DFCI), Boston. He is also the principal investigator of the Romee Lab for NK Cell Gene Manipulation and Therapy (https://romeelab.dana-farber.org) at DFCI. He did his medical school at GMC Srinagar, India followed by a medicine residency and hem-onc fellowship at the University of Minnesota. He did his post-doctoral fellowships in Dr. Jeff Miller’s lab at the University of Minnesota and Todd Feniger’s lab at Washington University in Saint Louis. He stayed on as faculty at WashU before being recruited to Dana Farber in early 2018.
His research at WashU helped described human memory-like NK cells. The research focus of his laboratory at DFCI is gene manipulation of the NK cells to enhance their anti-tumor function and simultaneously modulate the highly immune suppressive tumor microenvironment (TME). His lab has recently developed a novel TCR-mimetic CAR against NPM1 mutant AML which is moving to an early-phase clinical trial in near future. Dr. Romee also leads several early-phase clinical trials combining NK cells with various immunomodulatory agents in advanced liquid and solid malignancies at DFCI.
Disclosure information not submitted.
Cancer Immunity & Immunotherapy Course
Tuesday, June 20, 2023
7:30 AM - 5:45 PM
